OTHER INFORMATION
−Removed: The information contained under "Supplemental Pharmacy Benefit Management Model Disclosure" in Exhibit 20.1 to this Form 10-Q is incorporated herein by reference.
+Added: Rule 10b5-1 Plan Elections
+Added: During the quarter ended June 30, 2023, the following 10b5-1 director and officer trading plan arrangement changes occurred:
+Added: On May 15, 2023 , David Cordani , Chairman and Chief Executive Officer , adopted a 10b5-1 sales plan.
+Added: Cordani's plan provides for the sale of up to 33,911 shares of The Cigna Group common stock and the exercise of vested stock options and the associated sale of up to 142,801 shares of The Cigna Group common stock through May 10, 2024.
+Added: On May 23, 2023 , Nicole Jones , Executive Vice President and General Counsel , adopted a 10b5-1 plan.
+Added: Jones' plan provides for the sale of up to 15,619 shares of The Cigna Group common stock through May 10, 2024.
+Added: On May 26, 2023 , Cynthia Ryan , Executive Vice President and Chief Human Resources Officer , adopted a 10b5-1 plan.
+Added: Ryan's plan provides for the sale of up to 3,187 shares of The Cigna Group common stock and the exercise of vested stock options and the associated sale of up to 10,040 shares of The Cigna Group common stock through May 10, 2024.
+Added: These trading plans were entered into during an open insider trading window and are intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934 and the Company's policies regarding insider transactions.
INDEX TO EXHIBITS
4 unchanged sentences
Filed by the registrant as Exhibit 3.3 to the Current Report on Form 8-K on February 13, 2023.
−Removed: 4.1(g) Supplemental Indenture No.
−Removed: 6 dated as of March 7, 2023, between The Cigna Group and U.S.
−Removed: Bank Trust Company, National Association, as trustee
−Removed: Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on March 7, 2023 and incorporated herein by reference.
−Removed: 10.31 Offer letter for Noelle Eder dated July 22, 202 0
−Removed: Filed herewith.
−Removed: 20.1 Supplemental Pharmacy Benefit Management Model Disclosure
−Removed: Filed herewith.
+Added: 10.1 Revolving Credit and Letter of Credit Agreement, dated as of April 27, 2023, with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc.
+Added: and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners.
+Added: Filed by the registrant as Exhibit 10.1 to the Current Report on Form 8-K on April 28, 2023.
31.1 Certification of Chief Executive Officer of The Cigna Group pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934
6 unchanged sentences
Furnished herewith.
−Removed: 101 The following materials from The Cigna Group's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in Inline XBRL (eXtensible Business Reporting Language):
+Added: 101 The following materials from The Cigna Group's Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, formatted in Inline XBRL (eXtensible Business Reporting Language):
(i) the Consolidated Statements of Income;
7 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: August 3, 2023
THE CIGNA GROUP
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.